To explore the mechanistic consequences of the combination on MEK/ERK signaling compared to monotherapy, we evaluated the changes in p-ERK1/2 levels across a number of cell lines (RKO (BRAFV600E, NF1V2205A; CRC), HPAF-II (KRASG12D; PaCa), (RPMI-8226 (KRASG12A; MM), NCI-H510 (NF1D2184G; SCLC)). The gene discussed is MAPK3; the disease is small cell lung carcinoma.